Neoadjuvant Chemoimmunotherapy for Lung Cancer – A Meta-Analysis
1. The overall survival had a significant hazard ratio (0.65) when comparing neoadjuvant chemoimmunotherapy to neoadjuvant chemotherapy. 2. Both groups...
Immunotherapy vs Chemoimmunotherapy in Older Adults With Advanced NSCLC
1. Adding chemotherapy to immunotherapy did not prolong OS or PFS, with non-significant differences in HR. 2. Grade 3 or...
Enobosarm in AR-positive, ER-positive, and HER2-Negative Advanced Breast Cancer
1. The clinical benefit rate was 32% in the 9 mg group and 29% in the 18 mg group. 2....
Biosimilar MW032 Vs Denosumab for Solid Tumor–Related Bone Metastases
1. The change of uNTx/uCr (a marker of bone resorption) was within the equivalence margin in the MW032 group and...
Updated Outcomes of Sacituzumab Govitecan in Resistant Advanced Urothelial Carcinoma
1. The objective response rate was 28% with a complete response of 5.6% and a partial response of 23%. 2....
Cemiplimab for Kidney Transplant Recipients With Cutaneous Squamous Cell Carcinoma
1. There was no kidney rejection noted in the cemiplimab for kidney transplant recipients. 2. Cemiplimab was found to have...
Optimizing Subtyping-Based Therapy in Triple-Negative Breast Cancer
1. The median progression-free survival was improved with the pooled subtyping-based therapy group compared to the control group (11.3 months...
Systemic Therapy and Stereotactic Body Radiotherapy in Oligoprogressive Breast Cancer or Lung Cancer
1. Progression-free survival in NSCLC was found to be significant with HR 0.41 compared to breast cancer which was non-significant...
Atezolizumab With Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
1. Progression-free survival was 4.1 months in the combination arm vs 2.2 months in the monotherapy arm with an HR...
Atezolizumab Monotherapy vs Chemotherapy In Advanced Urothelial Carcinoma
1. The median overall survival was similar between both groups, 15.2 months in atezolizumab monotherapy vs 13.3 months in chemotherapy,...
